FiercePharma1d
Sanofi's consumer health arm Opella secures FDA green light to pursue OTC Cialis study
After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...
Supplements company Physician's Choice explores sale, sources say
Physician's Choice, a U.S. maker of supplements and probiotics, is exploring a sale that could value the company at over $500 million, according to sources familiar with the matter. The founder-owned ...
clinicaltrialsarena6h
FDA lifts hold on Opella’s trial to support switch of Cialis to OTC drug
The US FDA has removed the clinical hold on a trial of Cialis (tadalafil) by Sanofi's consumer healthcare business, Opella.
STAT20h
Sanofi is warned by the FDA over ‘significant’ problems at a key manufacturing plant
The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...
Sanofi says FDA lifted clinical hold on trial for Cialis OTC switch
Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a ...
Sanofi's Opella: FDA Lifts Clinical Hold On OTC Cialis Trial
Sanofi's Consumer Healthcare division, Opella, announced that the U.S. Food and Drug Administration has lifted a clinical hold on its ...
Sanofi’s Growth Prospects and Undervalued Position Highlighted by Analyst Graham Parry
Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank ...
Sanofi to increase competition in atopic dermatitis market after Dupixent success
Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...
GlobalData on MSN12d
Sanofi reports positive results from trial of multiple myeloma drug candidate
The trial enrolled 531 adult subjects with multiple myeloma who had received at least one previous line of therapy.